AOBiome starts patient enrolment in Phase Ib/IIa trial to treat allergic rhinitis

US-based life sciences firm AOBiome has started enrolling patients in a Phase Ib/IIa clinical trial of its ammonia oxidising bacteria (AOB) product candidate to treat seasonal allergic rhinitis (SAR).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news